Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo Stock Exchange  >  Astellas Pharma Inc.    4503   JP3942400007

ASTELLAS PHARMA INC.

(4503)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Astellas Pharma Inc. : - XTANDI Approved by China NMPA for the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer

11/09/2020 | 09:25am EST

TOKYO - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., 'Astellas') today announced that the China National Medical Products Administration (NMPA) has approved XTANDI (enzalutamide soft capsules) for the treatment of adult men with non-metastatic castration-resistant prostate cancer (nmCRPC) with high risk of metastasis.

This is the second approved indication in China for enzalutamide, which is already available for adult men with metastatic castration-resistant prostate cancer (mCRPC) who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy (ADT), in whom chemotherapy is not yet indicated.

The approval is based on results from the PROSPER trial, a double-blind, placebo-controlled, pivotal Phase 3 trial that evaluated enzalutamide plus ADT versus placebo plus ADT in 1,401 men with nmCRPC and rapidly rising prostate-specific antigen levels. PROSPER met its primary endpoint of metastasis-free survival (MFS), with a median MFS of 36.6 months for men who received enzalutamide plus ADT, compared to 14.7 months with placebo plus ADT. Results demonstrated a 71 percent reduction in the risk of radiographic progression or death in men who received enzalutamide plus ADT, compared to placebo plus ADT (hazard ratio=0.29 [95% confidence interval: 0.24-0.35]; p

(C) 2020 Electronic News Publishing, source ENP Newswire

All news about ASTELLAS PHARMA INC.
01/14ACTINIUM PHARMACEUTICALS : and Astellas Announce Research Collaboration Focused ..
AQ
01/06ASTELLAS PHARMA INC. : - FDA Accepts for Priority Review the New Drug Applicatio..
AQ
2020ASTELLAS PHARMA : FDA Lifts Clinical Hold for Audentes Therapeutics' AT132 Trial
MT
2020ASTELLAS PHARMA : Reports XOSPATA in Combination with Azacitidine Did Not Meet E..
AQ
2020ASTELLAS PHARMA : Supports Recommendations of Task Force on Climate-related Fina..
AQ
2020ASTELLAS PHARMA INC. : - Expansion of the Domestic Logistics Platform for Pharma..
AQ
2020VIATRIS : Astellas and Viatris Announce Termination of Co-promotion, Succession ..
AQ
2020Japan shares slip for third day; all eyes on U.S. stimulus debate
RE
2020Japanese shares slip back as investors look to U.S. stimulus debate
RE
2020Astellas Pharma, Viatris Pharmaceuticals Japan to End Joint Sales Promotion o..
MT
More news
Financials
Sales 2021 1 272 B 12 253 M 12 253 M
Net income 2021 181 B 1 744 M 1 744 M
Net cash 2021 440 B 4 239 M 4 239 M
P/E ratio 2021 17,0x
Yield 2021 2,50%
Capitalization 3 130 B 30 155 M 30 153 M
EV / Sales 2021 2,11x
EV / Sales 2022 1,93x
Nbr of Employees 15 883
Free-Float 99,2%
Chart ASTELLAS PHARMA INC.
Duration : Period :
Astellas Pharma Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTELLAS PHARMA INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Average target price 2 268,18 JPY
Last Close Price 1 685,00 JPY
Spread / Highest target 114%
Spread / Average Target 34,6%
Spread / Lowest Target -2,08%
EPS Revisions
Managers and Directors
NameTitle
Kenji Yasukawa President, CEO & Representative Director
Yoshihiko Hatanaka Chairman
Naoki Okamura Representative Director & Vice President
Tomokazu Fujisawa Director
Hiroko Sakai Director
Sector and Competitors
1st jan.Capitalization (M$)
ASTELLAS PHARMA INC.5.71%30 155
JOHNSON & JOHNSON3.92%430 552
ROCHE HOLDING AG3.06%308 615
NOVARTIS AG2.73%220 726
MERCK & CO., INC.-1.00%204 882
PFIZER INC.-0.71%203 159